Navigation Links
Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
Date:2/26/2008

LARGO, Fla., Feb. 26 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF) (TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter and first half of FY2008.

Net sales, excluding royalty income, for the quarter ended December 31, 2007 increased to $1,512,361 compared with $1,438,153 in the quarter ending December 31, 2006, an increase of 5.2%. The increase was primarily the result of continued growth of the Company's C-Vue multifocal contact lenses, which increased approximately 12% in the current quarter, which was partially offset by sales of our replacement products lines that declined as expected.

Net Income for the quarter increased 70.2% to a record second quarter of $375,915, or $0.08 per diluted share, compared with $220,850, or $0.05 per diluted share in the prior-year period.

Royalty income for the quarter increased 20.3% to a record second quarter of $646,849 compared with $537,653 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to accelerate, resulting in the record quarterly royalty payment.

Income before taxes for the quarter ended December 31, 2007 increased 51.1% to $542,257, compared with $358,891 in the prior-year quarter. After recording income tax expense of $166,342, Unilens reported net income of $375,915, or $0.08 per diluted share. In the second quarter of FY2007, the Company reported net income of $220,850, or $0.05 per diluted share, after recording income tax expense of $138,041.

"We are pleased with our second quarter operating results, and based on currently available information, we anticipate a continuation of favorable revenue and profitability trends for the second half of the 2008 fiscal year," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Sales of our C-Vue brand disposable multi
'/>"/>

SOURCE Unilens Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
2. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
3. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
4. Vision restoration therapy shown to improve brain activity in brain injured patients
5. Mouse vision has a rhythm all its own
6. HEI, Inc. Announces Sale of RFID Division Assets
7. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
8. The aye-ayes have it: The preservation of color vision in a creature of the night
9. Can brain-injured, partially-blind stroke patients regain some of their lost vision?
10. HEI, Inc. Closes on Sale of RFID Division Assets
11. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ociation of Urology (EAU) and Europa Uomo, the Eur...state cancer, have entered into an,affiliated par...increase and improve,patient awareness in Europe ...Per-Anders Abrahamsson, Secretary-General of the E...ship, Europa Uomo will gain access to the latest i...
(Date:11/30/2009)...gs of gravy and dessert at the holiday table are e...ly thought. According to a new research report rec...tp://www.fasebj.org ), a diet that is high in fat ...ately cause our bodies to store too much fat. This... the already difficult task of converting high-fat...
(Date:11/30/2009)...SHENZHEN, China, Nov. 30 /PRNewswire-FirstCall/ - ...ical.com/ ) operating subsidiary Mellow Hope final...facturer of intravenous medication in India. This ...for Hard to Treat Diseases in the following quarte... company secures the supply of raw pharmaceutical ...
(Date:11/30/2009)...OLIS, Nov. 30 A new study has foun...Medicare insurance customers have a current intent... coverage. The figure is up from 20% in 2008. Ov...measure has been a leading indicator of actual swi...tention to switch actually will leave their curren...
(Date:11/30/2009)... and Senate bills stack up , , MONDAY, N...ills moving through the U.S. Congress differ in a ...ic reduction in the number of uninsured Americans....ntatives earlier this month would expand coverage ...g to debate a proposal to expand coverage to 94 pe...
Breaking Medicine News(10 mins):Health News:Western diets turn on fat genes 2Health News:Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical 2Health News:Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical 3Health News:More Seniors Considering Health Insurance Switch 2Health News:Health Reform: What's in It for You? 2Health News:Health Reform: What's in It for You? 3
...ent of coronary artery diseases, in which a thin p...ains the medicine// which can prevent scar formati...the stent without surgery introduces drug. Sir...g blood clots in the arteries without surgical met...
...e grapefruit is a thing to cheer for people suffer...t people with gum disease who ate two grapefruits ...eeding from the gums. The study was performed ...an increase in blood levels of vitamin C, known to...
...d that cold and flu drugs containing pseudoephedri... in an effort to limit illegal manufacturing of su...effect from January 1 in Queensland. Pharmacists h...often used as a raw material to manufacture speed ...
...ts from tissue that may have been illegally harves... positive for hepatitis // and syphilis, their la...re Memorial Hospital in Somers Point, N.J., and cl...ases within the last two weeks. The lawyer, And...
...tsunami waves had left over 25,000 people dead and...Indian Ocean countries. // One in five Thai tsun...year's disaster that forever changed the physical,...nami survivors are still suffering the post trauma...
...hat can detect the Hepatitis C virus using saliva ...i of Soroka University Medical Centre // in Israe... people without kidney functions whose blood must ... The researchers reported 100 percent success...
Other Medicine News:
(Date:11/30/2009)..., WALTHAM, Mass., Nov. 30 Decis... and advisory firms focusing on pharmaceutical and... virus drug market in Russia will grow nine percen...hing $327 million by 2013. This growth will be dri...lthcare and increased use of more-expensive therap...
(Date:11/30/2009)... , INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall...as approved Cymbalta® (duloxetine HCl) for th...order (GAD) in adults, Eli Lilly and Company (NYSE...d anxiety disorder can be a chronic illness, it is...treatment option that is effective in both the acu...
(Date:11/30/2009)..., BRIDGEWATER, N.J., Nov. 30 /PRNewswire-FirstCall...ng of an exclusive licensing agreement with Intell...for the emergency treatment of allergic reactions ... ,, "We are pleased to have this opportunity to...lions of people who are at risk of this life-threa...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 1China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 2China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 4China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 5China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 6China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 7China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 8China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 9China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 10China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 11China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 12China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 13Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 1Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 1MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 3MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 4
... American Association for Cancer Research,annual m...ire-FirstCall/ --,Medarex, Inc. today presented pr...tivity from two separate studies exploring the,eff... anti-CD70,antibody-drug conjugates. CD19 and CD70...conjugate approach to cancer therapy. They are,exp...
...the American Association for Cancer Research,(AACR...- Lorus,Therapeutics Inc. ("Lorus") today announce... and siRNA compounds at the 98th,Annual Meeting of... The first presentation titled, "Determination of ...docetaxel combination,treatment for NSCLC cells in...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 2Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 3Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 4Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 5
Revo Rotator Cuff Repair System
BioROC EZ Fasteners and Instrumentation
...a fully absorbable soft tissue anchor designed spe...s dynamic engagement into cancellous bone, its bro...de significant resistance to pullout in soft bone....ction provides the benefits of fixation strength c...
...ade; Ti Quick-T Fixation System is a single-step t...r secondary tissue fixation. This through tendon t...e Anchor combined with our pretied knot technology...e of PEEK-OPTIMA® LT3 polymer from Invibio. Th...
Medicine Products: